Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0162871 (
abdominal aortic aneurysm
)
8,664
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Abdominal aortic aneurysms are the result of a destructive process of the aortic media. The incidence of abdominal aortic aneurysms is increasing but the reasons remain unknown. The mechanical and structural characteristics of the abdominal aorta explain the frequency of acquired aneurysms at this location. Classically, atherosclerosis is the main etiologic factor, but the
abdominal aortic aneurysm
is distinguishable from the aged aorta and occlusive atherosclerotic disease by the apparent absence of a reparative process. Some authors have tried to differentiate aneurysmal disease from occlusive atherosclerotic disease. Atherosclerosis could lead to plaque and stenosis or, in some unknown circumstances, to atrophy of the media and aneurysmal dilation. Proteolytic enzymes within the aortic wall play an important role in the destruction of the extracellular matrix of the aortic wall.
Plasmin
could locally worsen the proteolysis. Inflammatory cells might be responsible for these proteolytic activities. Calcium could play a role in the activation of inflammatory cells. Genetic markers and familial grouping have been reported by several authors. The discovery of constitutional or acquired factors that could lead to activation of degradative phenomena within the aortic wall will facilitate the identification of patients at risk, and improve screening of asymptomatic aneurysms.
...
PMID:[Pathogenesis of acquired abdominal aortic aneurysms]. 182 79
This study examined whether intraluminal thrombus in abdominal aortic aneurysms (AAAs) is a source of fibrinolytic activity and proteolysis that could weaken the aneurysm wall.
Plasmin
, tissue plasminogen activator (tPA), and urokinase plasminogen activator (uPA) activity, plasminogen activator inhibitor 1 (PAI-1), and alpha2-antiplasmin (alpha2AP) antigen were measured in the
AAA
wall and juxtamural and luminal aspects of intraluminal thrombus in 18 patients. The aneurysm wall contained 100-fold higher tPA activity (1.06 +/- 0.34 [standard error of measurement] U/mg soluble protein) compared with juxtamural thrombus (JMT) (0.011 +/- 0.001 ) and luminal thrombus (LT) (0.01 +/- 0.001) (p < .00001) and over 6-fold higher uPA activity (29.3 +/- 3.4 IU/mg compared with the JMT (4.3 +/- 2.4, p = .00024) and LT (7.9 +/- 1.76, p = .0005). The LT had significantly lower levels of PAI-1 (1.26 +/- 0.34 ng/mg) than the
AAA
wall (2.08 +/- 0.51, p = .04) and the JMT (3.94 +/- 0.85, p = .007). The levels of alpha2AP in the wall (19.4 +/- 3.1 ng/mg) were lower than in the JMT or LT (43.0 +/- 7.9 ng/mg, p = .013, and 47.6 +/- 6.0 ng/mg, p = .002, respectively). There was no significant difference, however, in plasmin activity among the
AAA
wall, JMT, and LT. There were significant amounts of latent gelatinase B (matrix metalloproteinase [MMP]-9) in the
AAA
, JMT, and LT. Mean levels of activated MMP-9 activity were similar in the
AAA
, JMT, and LT.
Plasmin
activation of MMPs at the interface between intraluminal thrombus and the aneurysm wall may enhance proteolysis and accelerate aneurysm expansion.
...
PMID:Intraluminal thrombus enhances proteolysis in abdominal aortic aneurysms. 1684 17
The most important feature of
abdominal aortic aneurysm
(
AAA
) pathogenesis is an enzymatic degradation of elastic lamellae and extracellular matrix proteins particularly with participation of matrix metalloproteinases.
Plasmin
, which is responsible for the dissolution of fibrin in blood vessels, plays also a key role in the cascade for activation of the metalloproteinases. The purpose of this study was to evaluate the influence of selected polymorphisms in genes coding for tissue plasminogen activator (-7351 C/T polymorphism), urokinase-type plasminogen activator (1788 C/T polymorphism) and plasminogen activator inhibitor 1 (-675 4G/5G and -844 G/A polymorphism) on the susceptibility to
AAA
. We performed a case-control study of 153 polish patients hospitalized due to
AAA
and compared them with matched healthy control subjects. The polymorphisms were ascertained through genotyping by polymerase chain reaction and restriction digestion of amplified fragments or through high-resolution melting analysis. In this study we have found lower frequency of wild-type GG genotype of the -844G/A PAI-1 polymorphism in cases than in controls, what may suggest the protective effect of this genotype for the risk of
AAA
development. None of the remaining polymorphisms tested were associated with
AAA
occurrence.
...
PMID:The study of t-PA, u-PA and PAI-1 genes polymorphisms in patients with abdominal aortic aneurysm. 2445 21